Bristol-Myers Squibb to Acquire Celgene in Deal Worth $74 Billion
- Posted by ISPE Boston
- On January 7, 2019
Bristol-Myers Squibb and Celgene have announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. The Boards of Directors of both companies have approved the combination. The transaction is subject to approval by Bristol-Myers […]
Read More